Mannkind patents expiration
1. Afrezza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6906030 | MANNKIND | Carbon-substituted diketopiperazine delivery systems |
Sep, 2014
(9 years ago) | |
| US8133514 | MANNKIND | Carbon-substituted diketopiperazine delivery systems |
Sep, 2014
(9 years ago) | |
| US7276534 | MANNKIND | Carbon-substituted diketopiperazine delivery systems |
Sep, 2014
(9 years ago) | |
| US6663898 | MANNKIND | Carbon-substituted diketopiperazine delivery systems |
Sep, 2014
(9 years ago) | |
| US8394414 | MANNKIND | Method for drug delivery to the pulmonary system |
May, 2015
(8 years ago) | |
| US6428771 | MANNKIND | Method for drug delivery to the pulmonary system |
May, 2015
(8 years ago) | |
| US6071497 | MANNKIND | Microparticles for lung delivery comprising diketopiperazine |
May, 2015
(8 years ago) | |
| US6444226 | MANNKIND | Purification and stabilization of peptide and protein pharmaceutical agents |
Jun, 2020
(3 years ago) | |
| US7648960 | MANNKIND | Method for delivery of monomeric or dimeric insulin complexed to diketopiperazine microparticles |
Jun, 2020
(3 years ago) | |
| US6652885 | MANNKIND | Purification and stabilization of peptide and protein pharmaceutical agents |
Jun, 2020
(3 years ago) | |
| US7943178 | MANNKIND | Methods and compositions for delivering peptides |
Jun, 2020
(3 years ago) | |
| US8889099 | MANNKIND | Methods and compositions for delivering peptides |
Jun, 2020
(3 years ago) | |
| US8389470 | MANNKIND | Methods and compositions for delivering peptides |
Jun, 2020
(3 years ago) | |
| US8950397 | MANNKIND | Unit dose cartridge and dry powder inhaler |
Jul, 2021
(2 years ago) | |
| US8215300 | MANNKIND | Unit dose cartridge and dry powder inhaler |
Nov, 2022
(1 year, 5 months ago) | |
| US8156936 | MANNKIND | Unit dose capsules and dry powder inhaler |
Jan, 2023
(1 year, 3 months ago) | |
| US7305986 | MANNKIND | Unit dose capsules for use in a dry powder inhaler |
Jan, 2023
(1 year, 3 months ago) | |
| US7464706 | MANNKIND | Unit dose cartridge and dry powder inhaler |
Mar, 2023
(1 year, 2 months ago) | |
| US8146588 | MANNKIND | Unit dose capsules and dry powder inhaler |
Apr, 2023
(1 year, 8 days ago) | |
| US7943572 | MANNKIND | Superior control of blood glucose in diabetes treatment |
Aug, 2026
(2 years from now) | |
| US9283193 | MANNKIND | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
Sep, 2026
(2 years from now) | |
| US9717689 | MANNKIND | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
Sep, 2026
(2 years from now) | |
| US8729019 | MANNKIND | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
Dec, 2028
(4 years from now) | |
| US9662461 | MANNKIND | Dry powder drug delivery system and methods |
Jun, 2029
(5 years from now) | |
| US10342938 | MANNKIND | Dry powder drug delivery system |
Jun, 2029
(5 years from now) | |
| US9446133 | MANNKIND | Dry powder inhaler and system for drug delivery |
Jun, 2029
(5 years from now) | |
| US9192675 | MANNKIND | Dry powder inhaler and system for drug delivery |
Jun, 2029
(5 years from now) | |
| US8912193 | MANNKIND | Dry powder inhaler and system for drug delivery |
Jun, 2029
(5 years from now) | |
| US9393372 | MANNKIND | Dry powder drug delivery system |
Jul, 2029
(5 years from now) | |
| US8119593 | MANNKIND | Method of treating diabetes type 2 by metformin and an ultrarapid acting insulin |
Aug, 2029
(5 years from now) | |
| US8258095 | MANNKIND | Method of controlling glycemia by ultrarapid acting insulin without adjusting an insulin dose for meal content |
Aug, 2029
(5 years from now) | |
| US10046031 | MANNKIND | Use of ultrarapid acting insulin |
Aug, 2029
(5 years from now) | |
| US9943571 | MANNKIND | Use of ultrarapid acting insulin |
Aug, 2029
(5 years from now) | |
| US8623817 | MANNKIND | Method of treating diabetes type 2 by administering ultrarapid acting insulin |
Sep, 2029
(5 years from now) | |
| US9339615 | MANNKIND | Dry powder inhaler and system for drug delivery |
Oct, 2029
(5 years from now) | |
| US9511198 | MANNKIND | Dry powder inhaler and system for drug delivery |
Feb, 2030
(5 years from now) | |
| US8485180 | MANNKIND | Dry powder drug delivery system |
Mar, 2030
(5 years from now) | |
| US8551528 | MANNKIND | Diketopiperazine microparticles with defined specific surface areas |
Jun, 2030
(6 years from now) | |
| US8778403 | MANNKIND | Diketopiperazine microparticles with defined specific surface areas |
Jun, 2030
(6 years from now) | |
| US8734845 | MANNKIND | Diketopiperazine microparticles with defined specific surface areas |
Jun, 2030
(6 years from now) | |
| US10201672 | MANNKIND | Dry powder inhaler and system for drug delivery |
Aug, 2030
(6 years from now) | |
| US10500159 | MANNKIND | Apparatus and method for cryogranulating a pharmaceutical composition |
Nov, 2030
(6 years from now) | |
| US9358352 | MANNKIND | Dry powder drug delivery system and methods |
Feb, 2031
(6 years from now) | |
| US8227409 | MANNKIND | Diketopiperazine microparticles with defined isomer contents |
Mar, 2031
(6 years from now) | |
| US9597374 | MANNKIND | Use of ultrarapid acting insulin |
Oct, 2031
(7 years from now) | |
| US8424518 | MANNKIND | Dry powder inhaler and system for drug delivery |
Oct, 2031
(7 years from now) | |
| US8499757 | MANNKIND | Dry powder inhaler and system for drug delivery |
Feb, 2032
(7 years from now) | |
| US8636001 | MANNKIND | Dry powder inhaler and system for drug delivery |
Jul, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 27, 2017 |
Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient
Market Authorisation Date: 27 June, 2014
Treatment: Administration of a composition comprising a diketopiperazine and insulin.; Pulmonary administration of particles comprising a diketopiperazine and insulin.; Administration of a composition comprising...
Dosage: POWDER;INHALATION
AFREZZA family patents
